Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3692)	5/8/2001 9:08:23 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Bad news for BGEN's Avonex this morning - looks like SRA's drug beat it hands down in relapsing-remitting MS. An unusually strong result for a head-to-head trial. I exited my BGEN position in the pre-market this morning. BGEN will be a big drag on the biotech indices today and might well pull the rest of the biotechs down with it. I still am a firm believer in Amevive, and so am prepared to reenter at some point. Prudential has had a "sell" on BGEN - looks like they called this right, at least in the short-term. Note that Avonex still has some advantages - once a week injections instead of three times a week for one. Further, approval for Rebiff is still some way off - Peter Ginsberg at USBPJ thinks not until 2003. Peter